Candida albicans oral infection shapes innate immunity and recruitment of myeloid-derived suppressor cells
白色念珠菌口腔感染塑造先天免疫和骨髓源性抑制细胞的招募
基本信息
- 批准号:10665797
- 负责人:
- 金额:$ 38.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-14 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:Adoptive Cell TransfersAdoptive TransferAspartic EndopeptidasesBacterial InfectionsBenignCancer EtiologyCandida albicansCellsComplexCuesDiseaseEnzymesEpithelial AttachmentEpithelial CellsEpitheliumEquilibriumFutureGoalsHumanHyphaeIL17 geneImageImmuneImmune responseImmunityImmunologic FactorsIn VitroIndividualInfectionInflammatoryInflammatory ResponseIntegration Host FactorsInterleukin-1IntestinesInvadedKininogenaseLTB4R geneLeukotriene B4Macrophage-1 AntigenMeasuresMediatingModelingMucosal ImmunityMucous MembraneMusMycosesMyeloid-derived suppressor cellsNatural ImmunityNeutrophil InfiltrationNutrientOralOral candidiasisOral cavityOrganismOutcomePathogenesisPeptide HydrolasesPersonsProductionProliferatingProteinsRoleShapesSignal TransductionSymptomsT-LymphocyteThickTissuesTongueTumor EscapeVirulencearginasearmchronic infectioncytokinefungicidefungusgranulocytegut microbiomeimmune activationin vivoin vivo evaluationmouse modelmucosal sitemutantneutrophilnoveloral cavity epitheliumoral infectionoropharyngeal thrushoverexpressionpathogenpathogenic fungusrecruit
项目摘要
Project Summary
Candida albicans is a fungal commensal organism that causes oropharyngeal candidiasis (OPC) and
may disseminate systemically in immune compromised people. However, most healthy people have
oral
levels of C. albicans and it is a beneficial organism in the human gut microbiome. Mice infected with C.
albicans also have low numbers of oral fungi but have much higher numbers of
C. albicans in the gut so
that they are a good model to study what factors permit fungal tolerance at human mucosal sites.
C. albicans hyphae secrete the aspartyl protease Sap6 that mediates virulence in OPC, induces cytokine
release from oral epithelial cells, and initiates neutrophil recruitment. Oral infection by C. albicans in mice
caused recruitment of neutrophil “swarms” surrounding invading hyphae, as well as localized Arginase1
positive (Arg1+) granulocytic cells. These Arg1+ cells showed suppression of T cells thus identifying them
as myeloid-derived suppressor cells (MDSC). MDSCs have a well-known immunosuppressive role in
cancer causing tumor immune evasion, but also have a major role in host immune responses to bacterial
and fungal infections by favoring pathogen persistence and chronic infection. We are the first to identify
MDSC recruitment upon C. albicans oral infection but we do not know their role here. C. albicans infection
resulted in changes the oral epithelium (Ep) including expression of kallikrein (KLK5) proteases
accompanying increased Ep desquamation, and increased levels of tissue Arginase 1 (Arg1). The Aims
of this project are to 1) Identify in what manner Arg1 and KLK5 expression in oral Ep alters C. albicans
infection by examining the effect of Arg1 and KLK5 depletion; 2) Determine how C. albicans induces
neutrophil swarming and recruitment of MDSCs in vitro by using live imaging of neutrophil swarming
induced by C. albicans and Sap6 and to measure fungicidal activity of MDSCs; and 3) Ascertain the
contribution of MDSCs in oral and gut Ca infection in vivo by comparing C. albicans infection in tongue
and intestine following MDSC depletion or adoptive transfer of MDSCs. The goal of this proposal is to
determine the function of MDSCs in mucosal immunity as well as how Arginase metabolites and KLK5
expression control the final outcome of fungal infection. It is proposed that MDSCs are a novel and
unexplored arm of oral epithelial immunity that contribute to oral or gut tolerance of fungal pathogens.
The long-range goal of this project is to understand host response to C. albicans and that will guide future
strategies to reduce the immune escape of C. albicans and add to our understanding of host tolerance.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mira Edgerton其他文献
Mira Edgerton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mira Edgerton', 18)}}的其他基金
Candida albicans oral infection shapes innate immunity and recruitment of myeloid-derived suppressor cells
白色念珠菌口腔感染塑造先天免疫和骨髓源性抑制细胞的募集
- 批准号:
10501899 - 财政年份:2022
- 资助金额:
$ 38.12万 - 项目类别:
Candida albicans secreted protease Sap6 engages epithelial protease-activated receptors PAR2 and NLRP3
白色念珠菌分泌的蛋白酶 Sap6 与上皮蛋白酶激活受体 PAR2 和 NLRP3 结合
- 批准号:
10428637 - 财政年份:2021
- 资助金额:
$ 38.12万 - 项目类别:
Candida albicans secreted protease Sap6 engages epithelial protease-activated receptors PAR2 and NLRP3
白色念珠菌分泌的蛋白酶 Sap6 与上皮蛋白酶激活受体 PAR2 和 NLRP3 结合
- 批准号:
10300121 - 财政年份:2021
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
2449485 - 财政年份:1999
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
6164397 - 财政年份:1999
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
6516337 - 财政年份:1999
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
6362916 - 财政年份:1999
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
6634566 - 财政年份:1999
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
2015439 - 财政年份:1997
- 资助金额:
$ 38.12万 - 项目类别:
HISTATIN RECEPTORS AS DRUG TARGETS FOR ORAL CANDIDIASIS
组氨酸受体作为口腔念珠菌病的药物靶点
- 批准号:
2856658 - 财政年份:1997
- 资助金额:
$ 38.12万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 38.12万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 38.12万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 38.12万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 38.12万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 38.12万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 38.12万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 38.12万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 38.12万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 38.12万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 38.12万 - 项目类别:














{{item.name}}会员




